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Abstract
Background—Comorbid anxiety in bipolar disorder (BD) is associated with greater illness 
severity, reduced treatment response, and greater impairment. Treating anxiety in the context of 
BD is crucial for improving illness course and outcomes. The current study examined the 
feasibility, acceptability and preliminary efficacy of the Unified Protocol (UP), a transdiagnostic 
cognitive behavioral therapy, as an adjunctive treatment to pharmacotherapy for BD and comorbid 
anxiety disorders.
Methods—Twenty-nine patients with BD and at least one comorbid anxiety disorder were 
randomized to pharmacotherapy treatment-as-usual (TAU) or TAU with 18 sessions of the UP (UP
+TAU). All patients completed assessments every four weeks to track symptoms, functioning, 
emotion regulation and temperament. Linear mixed-model regressions were conducted to track 
symptom changes over time and to examine the relationship between emotion-related variables 
and treatment response.
Results—Satisfaction ratings were equivalent for both treatment groups. Patients in the UP+TAU 
group evidenced significantly greater reductions over time in anxiety and depression symptoms 
(Cohen’s d’s >.80). Baseline levels of neuroticism, perceived affective control, and emotion 
regulation ability predicted magnitude of symptom change for the UP+TAU group only. Greater 
change in perceived control of emotions and emotion regulation skills predicted greater change in 
anxiety related symptoms.
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Limitations—This was a pilot feasibility and acceptability trial; results should be interpreted 
with caution.
Conclusions—Treatment with the UP+TAU was rated high in patient satisfaction, and resulted 
in significantly greater improvement on indices of anxiety and depression relative to TAU. This 
suggests that the UP may be a feasible treatment approach for BD with comorbid anxiety.
Keywords
Bipolar disorder; anxiety disorders; transdiagnostic; cognitive behavioral therapy; emotion 
regulation
Introduction
Bipolar disorders (BD), including bipolar I, bipolar II, cyclothymia, “other specified” and 
“unspecified” bipolar and related disorders, affect approximately 4% of the population in the 
U.S. (Kessler et al., 2005) and 2% of the population worldwide (Merikangas et al., 2011). 
BD is characterized by the occurrence of (hypo)manic episodes and depressive mood 
episodes. While the mean duration of discrete mood episodes is about 13 weeks (Solomon et 
al., 2010), the majority of patients also have persistent comorbid anxiety symptoms or 
anxiety disorders. Over 86% of patients with BD endorse a lifetime diagnosis of a comorbid 
anxiety disorder (Merikangas et al., 2007) with over a third of BD patients meeting 
diagnostic criteria for a current comorbid anxiety disorder that warrants treatment at any 
given time (Simon et al., 2004). The presence of comorbid anxiety has been identified as an 
independent marker of greater BD severity, and is associated with greater chronicity, reduced 
treatment response, and greater functional impairment (Deckersbach et al., 2014; Goldberg 
& Fawcett, 2012; J. H. Lee & Dunner, 2008; Otto et al., 2006). Thus, the reality of BD 
extends beyond traditionally emphasized discrete mood episodes and is often exacerbated by 
the presence of anxiety. This point is reinforced by the recent addition of an “anxious 
distress” specifier to BD in the revised Diagnostic and Statistical Manual, 5th Edition 
(DSM-5; (APA, 2013). Anxiety in the context of BD therefore represents a crucial target for 
improving illness course and outcomes.
Existing treatments thus far do not adequately meet the need to address anxiety in the 
context of BD (Vazquez, Baldessarini, & Tondo, 2014). Although pharmacotherapy is the 
front-line treatment for BD, pharmacotherapy for the treatment of comorbid anxiety in BD 
faces significant challenges. Specifically, both SSRIs and benzodiazepines, the first-line 
pharmacological treatments for anxiety, may be contraindicated in the context of BD (El-
Mallakh & Hollifield, 2008; Freeman, Freeman, & McElroy, 2002; Pacchiarotti et al., 2013; 
Sasson, Chopra, Harrari, Amitai, & Zohar, 2003). Though the negative effects of SSRIs in 
BD are under debate, there is evidence that they interact with mood stabilizers, aggravate 
side effects of other medications, and may trigger mania onset (Allain et al., 2016; Post et 
al., 2006; Tondo, Vazquez, & Baldessarini, 2010). Benzodiazepines carry the risk of 
developing dependence, which is particularly problematic for BD patients who show high 
incidences of comorbid substance use disorders (Brunette, Noordsy, Xie, & Drake, 2003). 
Cognitive-behavioral therapy (CBT), highly effective in the treatment of primary anxiety 
disorders, may offer a viable treatment alternative to pharmacotherapy for the treatment of 
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anxiety in BD. Thus far, however, very few studies of CBT for anxiety in BD have been 
conducted, and those that do exist are limited to targeting a single specific anxiety 
disorder(Provencher, Hawke, & Thienot, 2011; Stratford, Cooper, Di Simplicio, Blackwell, 
& Holmes, 2015). This approach is problematic, as individuals with BD often present with 
multiple anxiety disorder diagnoses, begging the question of which specific anxiety disorder 
to target for treatment.
The current study aims to address the need for improved treatments for anxiety in the 
context of BD by testing the feasibility, acceptability and preliminary efficacy of the Unified 
Protocol for Transdiagnostic Treatment of Emotional Disorders (UP; Barlow et al., 2010a; 
Barlow et al., 2010b) as an adjunctive treatment to psychopharmacological treatment-as-
usual (TAU) for BD and comorbid anxiety disorders. The UP is a transdiagnostic CBT 
treatment developed to address common core processes that underlie the full range of 
anxiety and mood disorders. Specifically, evidence from genetics, cognitive and affective 
neuroscience, and behavioral and physiological data shows that individuals across these 
disorder spectrums demonstrate a biological and psychological vulnerability towards 
increased affective lability relative to healthy controls, and exhibit a tendency to experience 
affective states as aversive, uncontrollable and unpredictable (Barlow, Sauer-Zavala, Carl, 
Bullis, & Ellard, 2014). These patterns are coupled with maladaptive and ineffective 
attempts to control, avoid or regulate emotional experiences. The UP specifically targets 
such deficits in emotion processing that are evident across mood and anxiety disorders 
including bipolar disorder.
The rationale for testing the UP for the treatment of BD and comorbid anxiety is twofold: 
First, given the high rates of comorbity in BD referenced above, an approach that accounts 
for transdiagnostic processes offers greater parsimony. In addition to addressing symptoms 
of anxiety in BD, this approach may benefit other co-occurring disorders, such as substance 
dependence. Second, the UP specifically targets deficits in emotion regulation and 
emphasizes the adoption of more adaptive emotion regulation skills both through skills 
training and emotion exposures. BD are disorders particularly characterized by both emotion 
lability and the inability to adaptively manage or regulate emotional experiences, which are 
further intensified by anxiety symptoms (Heissler, Kanske, Schonfelder, & Wessa, 2014). 
Chronic emotion dysregulation can permeate every domain of functioning for individuals 
struggling with BD, and is linked to impulsive, risky or self-destructive behaviors, 
interpersonal problems, disruptions in work productivity, and even suicidality (Kessler et al., 
2006; Muhtadie, Johnson, Carver, Gotlib, & Ketter, 2014; Samalin, de Chazeron, Vieta, 
Bellivier, & Llorca, 2016; Swann, Lijffijt, Lane, Steinberg, & Moeller, 2009; Van Rheenen, 
Murray, & Rossell, 2015). BD patients report investing more time and effort in trying to 
regulate their emotions than healthy controls, and engage maladaptive emotion regulation 
strategies such as rumination and suppression more frequently (Gruber, Harvey, & Gross, 
2012; Thomas, Knowles, Tai, & Bentall, 2007; Van der Gucht, Morriss, Lancaster, 
Kinderman, & Bentall, 2009; Van Rheenen et al., 2015; Wolkenstein, Zwick, Hautzinger, & 
Joormann, 2014). Further, emotion dysregulation in BD is associated with worsened 
neuropsychological deficits (e.g. behavioral slowing, poor working memory, impaired 
executive control), worse subjective psychosocial functioning (Hoertnagl et al., 2011), more 
frequent mood episodes, and worse course of illness (Kanske, Heissler, Schonfelder, 
Ellard et al. Page 3
J Affect Disord. Author manuscript; available in PMC 2018 September 01.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Forneck, & Wessa, 2013)., It has been postulated that difficulties in regulating emotions 
underlie the chronic course of the illness (Phillips & Vieta, 2007; Wolkenstein et al., 2014). 
Thus, treatments that focus on targeting and improving emotion regulation skills may be 
particularly beneficial for individuals with BD.
Given the UP’s focus on ameliorating emotion dysregulation using a transdiagnostic 
framework, we hypothesized that the UP may be particularly suited to address BD with 
comorbid anxiety. The UP has demonstrated efficacy in the treatment of a range of co-
occurring anxiety and unipolar mood disorders (Barlow et al., submitted; Ellard, Fairholme, 
Boisseau, Farchione, & Barlow, 2010; Farchione et al., 2012), and preliminary data suggests 
efficacy for bipolar mood disorders as well (Ellard, Deckersbach, Sylvia, Nierenberg, & 
Barlow, 2012). The current study investigates the feasibility and acceptability of this 
approach as applied to the treatment of BD and comorbid anxiety disorders as an adjunctive 
treatment to standardized psychopharmacological treatment as usual (TAU). In addition, we 
evaluated the preliminary efficacy of this approach on improvement in bipolar mood and 
anxiety symptoms and psychosocial functioning, relative to pharmacological TAU alone.
Given the focus of the UP on targeting underlying emotion dysregulation as a 
transdiagnostic, trait-like factor affecting mood and anxiety symptoms, we additionally 
examined specific factors related to emotion regulation, perceptions of controllability of 
emotions, and temperamental variables related to neuroticism and affective behavioral styles 
as a secondary, exploratory aim of this study, in order to better clarify potential treatment-
related mechanisms of action. Specifically, we conducted exploratory analyses to determine 
whether baseline characteristics related to these factors predicted treatment response across 
treatment groups. Similarly, in order to begin to understand potential mechanisms of 
treatment effects, we examined whether treatment-related changes on these trait-like 
variables differentially predicted symptom change across treatment groups.
Methods
Participants
Participants were recruited from the Massachusetts General Hospital Bipolar Clinic and 
Research Program. The Massachusetts General Hospital Institutional Review Board 
approved the study protocol and participants provided written informed consent prior to the 
initiation of any study procedure. Psychiatric diagnoses were confirmed using the Structured 
Clinical Interview for DSM-IV (SCID-IV; First, Spitzer, Gibbon, & Williams, 1997) and 
mood episode severity was assessed using the Hamilton Depression Rating Scale (HAM-D; 
Hamilton, 1960) and Young Mania Rating Scale (YMRS; Young, Biggs, Ziegler, & Meyer, 
1978). Eligible participants (N = 29, female = 17, Mage = 43.72, range 22–64) met criteria 
for bipolar disorder (BD–I, n=27; or BD–II, n=2), did not meet criteria for a major 
depressive or manic episode at study entry (HAM-D-17 ≤16 and YMRS ≤12), and met 
criteria for at least one of the following anxiety disorders: generalized anxiety disorder (n = 
19), panic disorder (n = 14), social phobia (n = 18). All participants were required to have at 
least 3 months of stability on their current dosage(s) of medication(s), and were asked to 
maintain this dosage throughout the study period. Stable maintenance pharmacotherapy was 
defined as maximum tolerated dosages according to Texas Implementation of Medication 
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Algorithm (Suppes et al., 2005), as prescribed by a psychiatrist. Individuals were excluded if 
they endorsed current suicidal ideation; history of seizure disorder, brain injury, or 
neurological disease; met criteria for a psychotic disorder; reported psychotic symptoms; 
met criteria for a substance use disorder within the past 12 months, or had received 
electroconvulsive therapy (ECT) within the six months preceding study enrollment. Eligible 
participants were randomly assigned to either continued psychopharmacological treatment 
as usual (TAU) or TAU plus 18 weekly sessions of the UP (UP+TAU). Individuals randomly 
assigned to the TAU group were offered 18 weekly individual treatment sessions with the 
UP at the completion of the study (month 6). This six-month wait period for commencement 
of UP sessions was comparable to the standard wait time for assignment to a CBT therapist 
at our clinic. Thirteen individuals were randomly assigned to the UP+TAU arm and 16 
individuals to the TAU arm. See Figure 1 for a summary consort chart.
Procedure
All participants underwent a thorough baseline assessment, which included a combination of 
clinician-administered and self-report measures of mood and anxiety symptoms, functional 
impairment, personality, and emotion regulation (see Measures below). These assessments 
were repeated for all participants every four weeks for a period of six months. All 
assessments were conducted by blind independent evaluators (IE). IEs were masters-level 
doctoral students or doctoral-level clinicians trained to certification on all assessment 
measures. Certification procedures included attending a formal assessment training session 
and viewing and rating patient interviews. To certify, IEs were required to score within one 
point of an expert rater on clinical measures (T.D., K.E., or A.N.). To maintain IE blindness, 
monthly study assessments were scheduled on different days than therapy visits. Study IE’s 
did not encounter study participants at any time other than during assessment visits.
TAU group—Participants randomized to TAU continued usual care under their treating 
psychiatrist, and were asked to refrain from psychotherapy for the duration of study 
participation (six months). Participants repeated clinician-administered and self-report 
assessments every four weeks (baseline through six months). Participants were closely 
monitored for worsening of symptoms or adverse events during this period. Medication 
usage, including any medication or dosage changes, was tracked and recorded during each 
assessment.
UP+TAU group—Participants randomized to UP+TAU continued care under their treating 
psychiatrist and completed clinician-administered and self-report assessments every four 
weeks (baseline through six months) following the same procedures as the TAU group. 
Additionally, they received 18 weekly one-hour treatment sessions with the UP. The UP 
intervention comprises 8 modules: (1) motivation enhancement, (2) psychoeducation, (3) 
present-focused awareness training, (4) cognitive appraisal and reappraisal, (5) emotion 
avoidance and emotion driven behaviors, (6) interoceptive awareness and exposure, (7) 
emotion exposure, and (8) relapse prevention. Participants were encouraged to complete 
weekly homework and to practice learned skills between sessions. In Module 1, patients 
identify concrete goals and personal markers of change for the treatment. Module 2 
emphasizes the adaptive nature of emotions and their bidirectional relationships with 
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behaviors, thoughts and physiological sensations. During Module 3, patients practice 
mindfulness skills aimed at shifting and focusing their attention to the present moment and 
noticing thoughts, physiological sensations and behaviors as they are occurring in real time. 
Emphasis is placed upon identifying automatic associations between specific thoughts, 
feelings and behaviors. Modules 4 through 6 focus on identifying maladaptive automatic 
emotion-related responses and modifying these responses towards more adaptive outcomes. 
Specifically, Module 4 introduces skills for modifying maladaptive, automatic emotion-
related appraisals and core beliefs. Module 5 introduces skills for countering automatic, 
emotion-driven behaviors and behavioral avoidance. Module 6 focuses on identifying the 
connection between physiological, visceral states and specific thoughts and behaviors, and 
increasing awareness and tolerance of physiological sensations through interoceptive 
exposures. Module 7 focuses on integrating all skills learned in Modules 3 through 6 by 
conducting in- and between-session planned exposures to emotion-provoking scenarios in 
which patients practice applying skills from treatment. Finally, sessions ended in module 8 
with the therapist and patient reviewing treatment concepts, differentiating between 
symptom recurrence and disorder relapse, and reflecting on how the practiced skills could 
continue to be implemented in the patient’s life. For a more detailed description of the UP 
approach see Barlow et al., 2010; Ellard et al., 2010, 2012; Farchione et al., 2012. All 
treatment sessions were conducted by a doctoral-level psychologist (K.E.), a co-developer of 
the UP fully certified in the treatment, with eight years of prior experience in CBT. 
Supervision of therapy sessions was provided weekly by a licensed clinical psychologist 
(T.D.).
Assessment Measures
Treatment feasibility/acceptability—Treatment feasibility and acceptability were 
tracked throughout the study. To track treatment feasibility in the UP+TAU group, the 
treating clinician rated treatment adherence at the end of each weekly in-person session 
using the Homework-Compliance Scale (HCS; Primakoff, Epstein, & Covi, 1986). Scores 
ranged from 1 (“the patient did not attempt assigned homework”) to 6 (“the patient did more 
of the assigned homework than was requested”). To track treatment acceptability, all 
participants completed the Client Satisfaction Questionnaire-8 (CSQ-8; Larsen, Attkisson, 
Hargreaves, & Nguyen, 1979) at each monthly assessment visit. The CSQ-8 is an eight-item, 
self-report measure developed to assess satisfaction with a specific healthcare or counseling 
service. Higher scores indicate greater satisfaction with treatment received. The CSQ-8 has 
demonstrated high internal consistency, and high correlation with treatment termination 
status and change in client-reported symptoms (Attkisson & Zwick, 1982).
Primary symptom outcomes—Changes in mood symptoms and functioning were 
monitored using semi-structured interviews and self-report questionnaires, in order to track 
concurrence between clinician-administered measures and patient subjective report.
Hamilton Depression Rating Scale, 17-item version (HAM-D-17; Hamilton, 
1960): Clinician-rated depressive symptoms were assessed monthly using 17-item HAM-
D-17. The HAM-D-17 is a well-established clinician-rated structured interview with high 
reliability and validity, recently re-evaluated in a large meta-analysis (Trajković et al., 2011).
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Quick Inventory of Depressive Symptomatology (QIDS-SR; Rush et al., 2003): Self-
report depressive symptoms were assessed monthly using the QUIDS-SR, a 16-item 
measure designed to assess primary symptoms of depression. The QIDS-SR has been 
validated in chronic depression (Rush et al., 2003) as well as in outpatients with bipolar 
disorder (Trivedi et al., 2004).
Hamilton-Anxiety Rating Scale (HAM-A; Hamilton, 1959): Clinician-rated anxiety was 
assessed using the HAM-A, a well-established 14-item structured interview used to assesses 
anxiety-related symptoms. The HAM-A has consistently demonstrated high inter-rater 
reliability and validity (Bruss, Gruenberg, Goldstein, & Barber, 1994; Shear et al., 2001).
Anxiety Symptoms Questionnaire (ASQ; Pollack et al., 2011): Self-report anxiety was 
assessed using the ASQ, a 17-item questionnaire, which measures both the intensity (ASQ-I) 
and frequency (ASQ-F) of psychological and somatic symptoms of anxiety. Participants 
separately rated the intensity and frequency of each symptom on a scale of 0–10, from 
“none” to “frequently.” Higher total scores indicate greater anxiety. The ASQ has 
demonstrated good construct validity and test-retest reliability (Pollack et al., 2011).
Young Mania Rating Scale (YMRS; Young et al., 1978): Clinician-rated (hypo)mania 
symptoms were assessed monthly using the YMRS. The 11-item YMRS is the most widely 
studied instrument for mania, and its reliability and validity are high (Young et al., 1978).
Altman Self-Rating Mania Scale (ASRM; Altman, Hedeker, Peterson, & Davis, 
1997): Self-reported symptoms of (hypo)mania were assessed using the ASRM, a 5-item 
instrument designed to assess presence and severity of manic symptoms. The ASRM has 
demonstrated high test-retest reliability and validity (Altman et al., 1997).
Longitudinal Interval Follow-up Evaluation - Range of Impaired Functioning Tool 
(LIFE-RIFT; Leon et al., 1999): Overall functioning was described with the LIFE-RIFT, a 
brief measure designed to assess overall functioning and degree of symptom interference in 
functioning in patients with affective disorders. It has demonstrated good reliability and 
validity. Higher scores on the above measures indicate greater severity or impairment. The 
LIFE-RIFT has demonstrated good internal consistency, reliability and validity in bipolar 
patients (Leon et al., 2000).
Secondary and exploratory outcomes—At monthly visits, participants also 
completed self-report questionnaires developed to measure specific factors related to 
emotion regulation, perceptions and reactions to and controllability of emotions, and 
temperamental variables related to affective behavioral styles, in order to assess potential 
mechanisms of treatment with the UP.
Affective Control Scale (ACS; Williams, Chambless, & Aherns, 1997): The ACS is a 42-
item self-report measure designed to assess perceived controllability of emotions and fear of 
loss of control when experiencing strong affective states. ACS subscales expand on the 
construct of fear of fear, including fear of anxiety, fear of depression, fear of anger, and fear 
of strong positive affective states. The ACS has demonstrated acceptable internal 
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consistency, test-retest reliability, and concurrent and divergent validity (Berg, Shapiro, 
Chambless, & Ahrens, 1998; Williams et al., 1997).
Anxiety Sensitivity Index (ASI; Reiss, Peterson, Gursky, & McNally, 1986)): The ASI is 
a 16-item, self-report measure developed to assess reactions to and perceptions of anxiety-
related symptoms. The ASI has demonstrated good test-retest reliability and construct 
validity (Peterson & Heilbronner, 1987).
Difficulties in Emotion Regulation Scale (DERS; Gratz & Roemer, 2004): The DERS is 
a 36-item, self-report measure developed to assess clinically relevant difficulties in emotion 
regulation, including 1) nonacceptance of emotional responses (Nonacceptance), 2) 
difficulties engaging in goal-directed behaviors (Goals), 3) impulse control difficulties 
(Impulse), 4) lack of emotional awareness (Awareness), 5) limited access to emotion 
regulation strategies (Strategies), 6) and lack of emotional clarity (Clarity). The DERS has 
demonstrated adequate internal consistency and adequate test-retest reliability (Fowler et al., 
2014; Gratz & Roemer, 2004). Whereas replication of the original six-factor solution has 
been inconsistent in healthy samples (Bardeen, Fergus, & Orcutt, 2012; Lee, Witte, Bardeen, 
Davis, & Weathers, 2016; Snow, Ward, Becker, & Raval, 2013), a recent study in severe 
mental illness found an acceptable fit with the six-factor solution (Fowler et al., 2014).
Rumination Subscale of the Reflection-Rumination Questionnaire (RRQ; Trapnell & 
Campbell, 1999): The RRQ was developed to differentiate between reflective versus 
ruminative self-focus. The RRQ Rumination subscale contains 12 items on a 5-point Likert-
type scale (1= “strongly disagree, 5 = “strongly agree”). Previous studies have shown good 
test-retest reliability and convergent validity(Trapnell & Campbell, 1999).
Response Styles Questionnaire, Ruminative Responses Subscale (RSQ-RRS; Nolen-
Hoeksema & Morrow, 1991): The 22-item RRS subscale of the RSQ captures responses to 
negative mood, asking participants to indicate how often they engage in various self-focused 
thought patterns (e.g. "I think back to other times I have been depressed”, "I think about how 
hard it is to concentrate", "I go away by myself and think about why I feel this way"). The 
RRS has demonstrated both internal consistency and construct validity as a stand-alone 
subscale (Nolen-Hoeksema & Morrow, 1991).
NEO Five-Factor Inventory (NEO-FFI; Costa & McCrea, 1992)): The NEO-FFI was 
developed to assess five domains of personality: (1) neuroticism (NEO-N), the tendency to 
experience negative emotions in response to stressors; (2) extraversion (NEO-E), the 
tendency towards increased sociability, positive emotionality, and general activity; (3) 
openness to experience (NEO-O), the tendency towards curiosity versus conservativeness; 
(4) agreeableness (NEO-A), the tendency towards altruistic and cooperative behavior; and 
(5) conscientiousness (NEO-C), the tendency towards thoughtful and deliberative planning 
and organization. The NEO-FFI contains 60 items rated on a 5-point Likert-type scale (1 = 
strongly disagree to 5 = strongly agree). Scores are used to derive five separate domain 
scores (12 items per domain). Each of the five domains of the NEO FFI has been found to 
possess adequate internal consistency and temporal stability (Costa & McCrea, 1992; 
Robins, Fraley, Roberts, & Trzesniewski, 2001).
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Behavioral Inhibition/Behavioral Activation Scale (BIS/BAS; Carver & White, 
1994)): The BIS/BAS was developed to measure behavioral inhibition (negative reactivity to 
aversive events) and behavioral activation (responsiveness to positive incentives and 
motivation and drive towards reward). It is comprised of 20 items with a 4-point Likert -type 
scale (1 = quite untrue of you; 4 = quite true of you). Four subscales are derived consisting 
of Behavioral Inhibition (BIS), Reward Responsiveness (BAS-Reward), Drive (BAS-Drive) 
and Fun Seeking (BAS-Fun). The BIS/BAS has demonstrated good reliability and 
convergent validity in clinical samples, and the original factor structure (Carver & White, 
1994) was replicated in patients with anxiety and mood disorders (Campbell-Sills, Liverant, 
& Brown, 2004).
Statistical Analyses
Descriptive data for the sample are presented as means with standard deviations (SD) for 
continuous variables and counts with proportions for categorical variables. We conducted 
chi-square analyses to evaluate group differences in gender, race, and ethnicity, and 
independent sample t-tests to evaluate baseline group differences in age, mood symptoms, 
functioning, emotion, and personality.
Primary outcomes—We conducted mixed-effects linear regression analyses to evaluate 
primary outcomes including treatment satisfaction, clinical symptoms, and functioning. 
Models included random intercept and slope over time and fixed effect for treatment. 
Treatment by time interactions were used to explore group differences in rates of change 
over time for outcome measures. Bonferroni corrections were applied. We used an intention-
to-treat (ITT) analysis approach, which is based on participants’ randomized assignments 
rather than their course during the study. Patients who completed at least one time point 
beyond randomization were included in the ITT analysis. The ITT approach aims to avoid 
artifacts such as non-random attrition that occurs during clinical trials. Additional mixed-
effects linear regressions were modeled for treatment completers (i.e. completion of monthly 
assessments through month six for TAU group, completion of all 18 treatment sessions for 
UP+TAU group). Effect sizes are reported as Cohen’s d.
Exploratory outcomes—Additional models were fit with baseline and change slopes for 
emotion regulation and personality measures as predictors of slope of mood and anxiety 
symptom change over the six months to explore the relationship between such process 
variables and symptom outcomes. Because we expect emotion-related variables to interact 
differently with each treatment approach, effects were computed separately for each 
treatment arm. Therefore, given the resultant small sample size and thus limited power, these 
results should be interpreted with caution.
Results
Baseline characteristics of the sample are included in Table 1. At study entry, treatment 
groups did not differ in gender, race, ethnicity, age, education, or medication load, with the 
exception of psychostimulants: four patients in the TAU group were taking stable doses of 
psychostimulants, whereas no patients in the UP+TAU group were taking psychostimulants. 
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No other significant differences in medication load were present. Treatment groups did not 
significantly differ on any clinical measure at baseline (p’s >.05) with the exception of the 
BIS, which was subsequently excluded from further analysis (Table 2).
Feasibility and Acceptability
Total attrition for all patients randomized to the study was 38% (11 out of 29 randomized; 
see Figure 1). Total attrition for patients who initiated treatment and completed at least one 
assessment timepoint (after four weeks of participation) was 25% (6 out of 24 treatment 
initiators). Attrition rates for the UP+TAU group were 38% of all randomized (5 out of 13), 
and 27% of treatment initiators (3 out of 11). Attrition rates for the TAU group were 38% of 
all randomized (6 out of 16), and 29% of treatment initiators (4 out of 14). For the UP+TAU 
group, reasons for dropout prior to treatment initiation were scheduling issues (n=1) and 
worsening of symptoms (n=1). Reasons for dropout after treatment initiation were 
discomfort with emotion exposures (n = 1), and unknown/lost to follow up (n=2). For the 
TAU group, reasons for dropout prior to treatment initiation were dissatisfaction with 
randomization assignment (n=2). Reasons for dropout after treatment initiation were non-
adherence to criteria of abstinence from outside psychotherapy (n=1), and unknown/lost to 
follow up (n=3). Although client satisfaction ratings were slightly higher for UP+TAU, there 
were no significant differences in satisfaction ratings between treatment conditions (CSQ: 
Mean diff = −1.62, t = −1.21, d = .51, 95% CI: −1.20, 4.82). For the UP +TAU group, 3 
participants dropped out after 3–4 treatment sessions; the remaining 8 completed all 18 
treatment sessions. Mean homework compliance score (HCS) was 3.78 (±1.49, range 1.50–
5.44), indicating on average patients completed “most but not all” of assigned homework.
Primary Symptom Change
Full results of linear mixed ITT models are presented in Table 3. Significantly greater linear 
reduction over time was found for the UP+TAU group in clinician rated anxiety scores 
(HAM-A: Mdiff = −5.91, t = 2.46, d = ..88, 95% CI: −10.82, −1.00) and both clinician and 
self-rated depression (HAM-D: Mdiff = −4.19, t = 2.36, d = .82, 95% CI: −7.80, −0.58; 
QIDS: Mdiff = −3.75, t = 2.71, d = 1.06, 95% CI: −6.60, − 0.90). No significant group 
differences were found in linear change in self-reported anxiety (ASQ), clinician rated or 
self-report mania symptoms (YMRS, ASRM) or symptom interference in functioning 
(LIFE-RIFT; Table 3). Analysis of completer data, defined as TAU patients who completed 
all six monthly assessments and UP+TAU patients who completed all 18 treatment sessions, 
linear mixed models showed significantly greater linear reductions among UP+TAU patients 
relative to TAU patients in clinician-rated anxiety (HAM-A: Mdiff = −6.58, t = 2.30, d = 
1.01, 95% CI: −12.53, −0.63), both clinician and self-rated depression (HAM-D: Mdiff = 
−4.44, t = 2.66, d = 1.06, 95% CI: −7.80, −0.58; QIDS: Mdiff = −5.19, t = 4.07, d = 1.67, 
95% CI: −7.82, −2.56), as well as symptom interference in functioning, although at trend 
level significance only (LIFE-RIFT: Mdiff = −2.01, t = 1.98, d= .86, 95% CI: −4.10, 0.09).
Emotion Regulation and Temperament Variables
No significant differences in linear change over time between treatment groups were found 
for any emotion processing related measures, including measures of the emotion regulation 
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(DERS), reaction to emotions (ACS), or anxiety sensitivity (ASI). In addition, no significant 
differences between treatment conditions were found for measures of temperament (NEO).
Exploratory Analyses: Relationship Between Symptom Change and Emotion Regulation 
Variables
Clinician-rated anxiety symptoms—Slope of change over time in clinician rated 
anxiety (HAM-A) scores was significantly negatively predicted by baseline measures of 
neuroticism (NEO-N), affective control (ACS), and emotion regulation difficulties (DERS) 
in the UP+TAU group, but not TAU group (Table 4). Thus, greater baseline neuroticism, fear 
of emotions, and emotion regulation deficits predicted less reduction in anxiety symptoms 
for the UP+TAU group only. There were no significant baseline predictors of HAM-A 
change slopes for TAU group. Change over time in affective control (ACS) and emotion 
regulation skills (DERS) positively predicted change in HAM-A scores for the UP+TAU 
group only, such that the greater the reduction of fear of emotions and emotion regulation 
deficits over treatment, the greater the reduction in anxiety symptoms. By contrast, change 
in agreeableness (NEO-A) positively predicted change in HAM-A scores for the TAU group 
only, such that greater increases in agreeableness predicted greater reduction in anxiety 
symptoms (Table 5).
Self-report anxiety symptoms—The slope of change in self-report anxiety frequency 
(ASQ-F) was significantly negatively predicted by baseline measures of deficits in emotion 
regulation strategies (DERS Strategies) in the UP+TAU group only, with a trend towards 
significance for neuroticism (NEO-N) anxiety sensitivity (ASI), and emotion interference in 
goals (DERS Goals; Table 4). Change in emotion regulation difficulties (DERS Goals, 
Strategies, Clarity, Impulsivity), as well as rumination (RRQ, RRS) and anxiety sensitivity 
(ASI) uniquely predicted change in self-reported anxiety frequency (ASQ-F) for the UP
+TAU group only, such that greater reductions in emotion regulation deficits, rumination and 
anxiety sensitivity predicted greater reductions in ratings of anxiety frequency. Change over 
time in acceptance of emotions (DERS Non-Acceptance) and affective control (ACS) 
significantly positively predicted change in self-report anxiety frequency for both treatment 
groups (Table 5), such that greater increases in acceptance of emotions and decreases in fear 
of emotions predicted greater reductions in anxiety frequency ratings.
Clinician-rated depression—Change in clinician-rated depression (HAM-D) over time 
was significantly negatively predicted by baseline measures of neuroticism (NEO-N), 
affective control (ACS), non-acceptance of emotions (DERS-Non-Acceptance subscale) and 
deficits in emotion regulation strategies (DERS Strategies subscale) for UP+TAU only. 
There were no significant baseline predictors of HAM-D change for TAU group. Both 
groups showed a trend towards significance for the effect of baseline agreeableness (NEO 
Agreeableness) on clinician-rated depression symptom (HAM-D) change (Table 4). Change 
over time in Neuroticism (NEO-N), Behavioral Activation (BAS Drive), and rumination 
(RRQ) uniquely predicted change in HAM-D scores in the UP+TAU group, such that greater 
decreases in neuroticism and rumination, and greater increases in behavioral activation 
predicted greater reductions in depressive symptoms. For TAU, change in NEO 
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Agreeableness uniquely predicted change in HAM-D. Both groups showed a trend towards 
significance for changes over time in emotion interference in goals (DERS Goals; Table 5).
Self-rated depression—Change in self-report depressive symptoms was negatively 
predicted at the trend level (p = .06) by baseline measures of Affective Control in UP+TAU 
group only. Baseline measures of NEO Agreeableness and Openness significantly positively 
predicted change in self-report depressive symptoms for TAU group, such that greater 
agreeableness and openness predicted greater change in depressive symptoms, with a trend 
towards significance for Behavioral Activation (Drive subscale; Table 4). Changes in NEO 
Agreeableness uniquely positively predicted change in self-report depressive symptoms for 
the TAU group (Table 5).
Symptom interference in functioning—Change in emotion regulation difficulties 
(DERS) significantly positively predicted change in symptom interference functioning 
(LIFE-RIFT) for the TAU group only, such that greater decreases in emotion regulation 
deficits predicted greater improvements in functioning (Table 4). There were no significant 
baseline predictors of change in symptom interference in functioning for either treatment 
group (Table 5).
Discussion
In the current study, we sought to determine the feasibility and acceptability of the UP, a 
transdiagnostic CBT treatment for emotional disorders, as applied to the treatment of BD 
with comorbid anxiety disorders. Results of this study suggest the UP is an acceptable 
treatment approach for individuals with BD and comorbid anxiety disorders. Patients rated 
their satisfaction with adjunctive treatment with the UP as equivalent to their satisfaction 
with pharmacotherapy treatment-as-usual, with a trend towards greater satisfaction with the 
UP. This is notable given the increased frequency of visits required to receive adjunctive 
therapy with the UP relative to receiving pharmacotherapy alone (once weekly as opposed to 
once every three months as in standard care with pharmacotherapy alone), and the increased 
expectation of patient engagement through assigned homework and skills practice. Attrition 
rates did not differ between treatment groups, and a greater proportion of treatment drop-
outs were due to dissatisfaction with treatment group assignment in the TAU group relative 
to the UP group, suggesting a preference for adjunctive CBT in this population. Three 
individuals dropped out of the UP+TAU condition after initiating treatment. One individual 
cited a discomfort with emotion exposures as a reason for discontinuation, whereas the other 
two discontinued for reasons unknown. One of these patients was attending college full-time 
and working part-time and had difficulty scheduling her sessions, and the other discontinued 
after accepting a full time nursing position. Therefore, the burden of attending weekly 
sessions may have been a factor for these patients, although both were unable to be re-
contacted so this could not be confirmed. The remaining 11 patients attended all 18 
treatment sessions. Patients were moderately compliant with assigned homework, on average 
completing most of the tasks assigned. This finding was also promising, as the added burden 
of homework compliance in the UP represents another potentially significant barrier to 
treatment acceptability and feasibility. Taken together, these results suggest the UP may be 
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an acceptable treatment strategy for individuals with BD and comorbid anxiety, although the 
results here are in a relatively small sample and should be interpreted with caution.
Attrition rates for UP treatment initiators in this study (27%) were comparable to existing 
studies of adjunctive individual-based psychosocial treatments for bipolar disorder in adults. 
Average reported post-treatment attrition rates for individual-based psychosocial treatments 
are approximately 25% (median 27%, range 9%–41%; (Ball et al., 2006; Fava, Rafanelli, 
Tomba, Guidi, & Grandi, 2011; Frank et al., 2005; Jones et al., 2015; Meyer & Hautzinger, 
2012; Miklowitz et al., 2007; Parikh et al., 2012; Reilly-Harrington et al., 2007; Scott et al., 
2006; Swartz, Frank, & Cheng, 2012; Zaretsky, Lancee, Miller, Harris, & Parikh, 2008; for 
recent reviews, see Chatterton et al., 2017; Salcedo et al., 2016; Stratford et al., 2015; Swartz 
& Swanson, 2014). For example, Parikh et al (2012), Zaretsky et al (2008), and Reilly-
Harrington et al (2007) report acute post-treatment attrition rates of 29%, 28% and 40% 
respectively for adjunctive individual CBT treatment conditions in their studies. Although 
acute post-treatment (9-month) attrition rates are not reported, the multisite Systematic 
Treatment Enhancement Program for Bipolar Disorder (STEP-BD) trial reports one-year 
attrition rates of 41% for the CBT treatment condition, 27% for Family Focused Therapy 
(FFT) and 32% for Interpersonal Social Rhythm Therapy (IPSRT), all treatments delivered 
adjunctive to pharmacotherapy TAU and compared to clinical management alone. Other 
studies have shown more favorable attrition rates for individual CBT adjunctive to TAU at 
acute post-treatment, including 9% in a study of Recovery-Focused CBT (Jones et al., 2015), 
17% for CBT (Scott et al., 2006), and 20% for CT (Ball et al., 2006). However, it should be 
noted that these studies do not provide information on comorbid anxiety disorders or anxiety 
symptom severity, whereas the previously referenced studies of adjunctive individual CBT 
report the presence of comorbid anxiety in approximately one-half to 100% of their samples 
(Parikh et al., 2012; Reilly-Harrington et al., 2007; Zaretsky et al., 2008). Therefore, 
comorbid anxiety may play a factor in higher relative attrition rates in studies of 
psychosocial treatment of BD, an area for further research.
In addition to feasibility and acceptability, we examined the efficacy of the UP in reducing 
depressive and anxious symptoms and improving functioning. Treatment with the UP plus 
pharmacotherapy resulted in greater reductions in clinician rated anxiety symptoms over 
time, and greater reductions in both clinician and self-report symptoms of depression over 
time, yielding large effect sizes. These findings held when using an ITT approach and when 
looking at treatment completers alone. It is interesting that treatment-related differences in 
self-rated depression symptoms were found, but no significant treatment-related difference 
in self-rated anxiety symptoms emerged, despite significant treatment-related differences in 
clinician-rated anxiety symptoms. This may be related to measurement artifact (the measure 
included in the current study only tracks frequency and intensity of anxiety symptoms, but 
not interference, hence there may be a ceiling effect), but might also be related to the 
relatively short time scale of this study. For many patients, physiological symptoms of 
anxiety are perceived as quite aversive, and therefore are particularly salient regardless of 
levels of interference. Although gains may be made in emotion regulation skills and 
therefore changes in depression-related symptoms (i.e. guilty ruminations, feelings of self-
worth, appetitive/vegetative changes) may be perceived, changes in reactions to anxiety-
related symptoms may only be achieved through repeated exposure to anxiety symptoms 
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over time, rather than during a brief study such as this. It should also be noted that in the 
present study, the explicit goal in the UP was not to eliminate anxiety but to change reactions 
to the experience of anxiety. Future studies should examine whether patients would endorse 
greater changes in self-reported frequency and intensity of anxiety over a longer-term follow 
up. Nevertheless, changes in clinician-rated anxiety suggest treatment with the UP decreased 
anxiety-related interference. Overall, preliminary results from this trial suggest that the UP 
may be a viable approach to addressing not only comorbid symptoms of anxiety, but also 
depression.
The paucity of existing trials examining the effects of psychosocial treatments on anxiety in 
BD, and in particular individual-based treatments, make it difficult to fully contextualize the 
results of the current trial. Of those that do exist, findings have been mixed. Reilly-
Harrington et al. (2007) conducted an open trial of individual-based CBT with an additional 
module specifically targeting anxiety adjunctive to pharmacotherapy TAU. Results from this 
trial found significant reductions on anxiety ratings, yielding small effects. However, this 
trial did not include a control condition, and was intended to specifically target rapid-cycling 
bipolar disorder. Therefore, it is unclear if similar effects would have been found in non-
rapid cycling bipolar patients, and additionally whether results would be superior to TAU. 
Fava et al. (2011) conducted a study of individual-based CBT plus Well-Being Therapy for 
subthreshold BD (cyclothymia) and anxiety, and found a significant post-treatment reduction 
in anxiety disorder comorbidity relative to TAU, with medium effects. Here again, however, 
the difference in BD population (cyclothymic as opposed to euthymic BD in the current 
study) makes it difficult to compare these results with the current trial. Trials of CBT for 
PTSD that have included BD patients have reported positive effects on reduction of PTSD 
symptoms overall (Mueser et al., 2008; Rosenberg, Mueser, Jankowski, Salyers, & Acker, 
2004), however these studies do not report results separately for BD patients, therefore the 
specific effects on anxiety symptoms in BD are unknown. Reports of the effects of group-
based psychosocial treatments on anxiety symptoms have been mixed. Studies of 
Mindfulness-Based Cognitive Therapy (MBCT) have had varying results, yielding small 
treatment-related effect size reductions in anxiety relative to TAU in one study (Perich, 
Manicavasagar, Mitchell, Ball, & Hadzi-Pavlovic, 2013), and large treatment-related effect 
size reductions in anxiety in two others (Ives-Deliperi, Howells, Stein, Meintjes, & Horn, 
2013; J. M. Williams et al., 2008). Studies of group CBT have also been inconclusive. 
Gonzalez-Isasi et al. (2012) found small treatment-related effect size differences in anxiety 
symptoms following group-based CBT relative to TAU. Da Costa et al. (2011) report 
significant within-group reductions in anxiety symptoms following group-based CBT, and 
no significant within-group reductions in anxiety symptoms following TAU. However, group 
comparisons are not reported, therefore specific treatment-related effects are unclear. Thus, 
there is a great need for further study of the effects of psychosocial treatments on anxiety in 
BD, which would allow the results of the current study to be more adequately 
contextualized.
The effects of adjunctive psychosocial treatments on depressive symptoms in BD have been 
more widely reported than anxiety, but trials are still sparse for individual-based treatments. 
Similar to the current study, moderate to large effect sizes for depression symptoms have 
been found with adjunctive, individual-based CBT relative to TAU (Ball et al., 2006; Jones 
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et al., 2015), psychoeducation (Zaretsky et al., 2008), or clinical management (Fava et al., 
2011; Miklowitz et al., 2007). Others have found no differences between CBT and TAU 
(Scott et al., 2012) or CBT and active psychosocial control conditions (group 
psychoeducation, Parikh et al., 2012; supportive psychotherapy, Meyer & Hautzinger, 2012). 
Effects of group-based treatments on depressive symptoms have been less robust. Medium 
effect size differences on depressive symptoms have been found relative to TAU for group-
based CBT (Gonzalez Isasi, Echeburua, Liminana, & Gonzalez-Pinto, 2014), and CT (Lam 
et al., 2003), and MBCT relative to a waitlist control (J. M. Williams et al., 2008). Others 
have reported no difference between group-based CBT and TAU (Costa et al., 2011; Gomes 
et al., 2011), MBCT and TAU (Perich et al., 2013), MBCT and waitlist (Ives-Deliperi et al., 
2013), or a Dialectic Behavior Therapy (DBT) skills-based group treatment and waitlist 
(Van Dijk, Jeffrey, & Katz, 2013). Thus, by comparison, the current study appears to be 
comparable to previously reported individual adjunctive psychosocial treatments in reducing 
symptoms of depression relative to pharmacotherapy TAU. However, the UP may also 
confer an added benefit by simultaneously ameliorating symptoms of anxiety.
In order to better understand potential mechanisms of action of the UP in BD with anxiety, 
we sought to examine how variables related to emotion processing, emotion regulation and 
temperament predicted symptom change in an additional, exploratory analysis. Analyses of 
these variables revealed intriguing differences in the interaction between emotion- and 
temperament-related variables and outcomes in each treatment condition. The efficacy of 
treatment with the UP was influenced by baseline levels of neuroticism, perceived affective 
control, and emotion regulation ability. These variables affected the impact of the UP on 
both anxiety- and depression-related symptoms. This finding was surprising given the UP’s 
specific focus on targeting underlying neuroticism and improving emotion regulation skills; 
the findings here suggest that, for the UP to be most effective, individuals may need to meet 
a certain threshold level of emotion regulation ability, and may need to exhibit a threshold 
level of neuroticism. The promising effects of the UP on anxiety and depressive symptoms 
on aggregate in this study suggests the UP is a viable treatment approach for individuals 
with BD and comorbid anxiety, however the interaction with emotion regulation and 
neuroticism-related variables suggest for a subset of individuals, in particular those with 
more severe emotion dysregulation and neurotic temperament, the beneficial effects may be 
out of reach. Anecdotally, individuals who exhibited greater emotional lability in session, 
and subsequently demonstrated greater psychosocial and functional instability between 
sessions, responded less well to treatment. These individuals tended to be less homework 
compliant, have more disruptive life circumstances between sessions, and have greater 
difficulty consolidating treatment concepts from one session to the next. These individuals 
also demonstrated a greater difficulty with the heavily didactic nature of the treatment, as 
evidenced by decreased homework compliance and greater difficulty comprehending key 
treatment concepts. Future studies are needed to determine whether adjustments to treatment 
delivery (e.g. intensive didactic sessions followed by repeated weekly exposure practice) or 
increasing baseline emotion regulation capacity through alternate intervention strategies (e.g. 
transcranial magnetic stimulation, transcranial direct current stimulation, attention or 
cognitive bias training) might improve the ability to benefit from treatment with the UP.
Ellard et al. Page 15
J Affect Disord. Author manuscript; available in PMC 2018 September 01.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
For the UP+TAU group only, greater change in perceived control of emotions and emotion 
regulation skills predicted greater change in anxiety related symptoms, endorsed by both 
clinician ratings and self-report, and greater changes in neuroticism and rumination 
predicted greater change in depressive symptoms. These findings, although requiring 
cautious interpretation, are promising in terms of purported mechanisms of action of the UP. 
The UP was developed to specifically target maladaptive emotion processing, both in terms 
of perceptions and regulation of emotions, deficits in both being related to an underlying 
temperament of increased neuroticism(Barlow et al., 2014). Results of the current trial 
suggest a significant relationship between changes in these variables and changes in 
symptoms related to treatment with the UP. This suggests the UP may be effective in 
ameliorating emotion dysregulation and accompanying neurotic symptoms in patients with 
BD and comorbid anxiety, although perhaps only for a subset of patients as discussed above. 
Changes in acceptance of emotions and perceived control of emotions significantly predicted 
self-rated frequency of anxiety for both treatment groups, suggesting that how people 
perceive and react to their anxious experiences influences how pervasive they view anxiety 
to be in their lives.
Although not a direct aim of this study, incidental findings of the relationship between 
temperamental and emotion regulation variables and pharmacological treatment-as-usual 
outcomes are intriguing. For the pharmacotherapy treatment-as-usual group alone, change 
over time in the temperamental measure of agreeableness significantly predicted clinician-
rated changes in anxiety and depression-related symptoms. Further, changes in 
conscientiousness and openness also predicted change in depressive symptoms. One 
hypothesis for these results is perhaps greater agreeableness, openness and 
conscientiousness correlates with greater medication compliance, an area for further inquiry.
Surprisingly, treatment groups did not differ in change over time on any secondary measure 
of emotion regulation, reactions to emotions, or temperament. This may be reflective of the 
more global, trait-like characteristics of these measures, which may be less sensitive to 
change over brief periods of time. Future studies are needed to understand potential 
longitudinal effects of the UP on these more static, emotion processing-related variables 
over time.
There are several limitations to consider when interpreting the results of this study. First, this 
was a small pilot feasibility and acceptability trial; therefore, the small sample size does not 
afford sufficient statistical power to detect anything less than a large effect size. The results 
should be considered exploratory and preliminary, with the intention of generating further 
testing of this approach. Second, as our intention was to test the feasibility and acceptability 
of the UP as an adjunctive treatment to pharmacotherapy TAU, we opted to preserve the 
TAU condition as close to clinical TAU as possible. Specifically, we wished to determine 
whether the adjunctive UP+TAU approach would be feasible and acceptable in this 
comorbid population given the added burden of weekly visits and homework. However, we 
cannot rule out that the additional clinician face-time received in the UP+TAU condition 
relative to TAU (weekly as opposed to monthly) may account for some differences in 
treatment response between conditions. We attempted to address this limitation in part by 
including assessments of purported treatment mechanisms of action (e.g. emotion regulation 
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skills). However, the difference in equipoise between treatments should nevertheless be 
considered as a limitation. Third, a single therapist conducted all treatment sessions for the 
UP+TAU group; therefore, we are unable to isolate effects of therapist from treatment 
effects, which limits the generalizability of the results. Fourth, in order to investigate more 
broadly the feasibility of this treatment approach as applied to a general treatment seeking 
population of patients with BD and anxiety, we opted for a heterogeneous bipolar sample 
including both bipolar I and bipolar II diagnoses. Although the sample included primarily 
patients with bipolar I (93%), given the small sample size in the current study we are unable 
to determine specific effects of treatment with the UP on discrete categories of BD patients. 
Finally, although attempts were made to maintain IE blindness to treatment condition, we 
cannot rule out the possibility that not all IE assessments were fully independent.
Conclusion
The current study sought to investigate the feasibility, acceptability, and preliminary efficacy 
of the UP as an adjunctive approach to pharmacotherapy treatment-as-usual in a population 
of BD patients struggling with comorbid anxiety symptoms. Results of this study are 
promising – patients in the UP group found the treatment no less satisfactory than 
pharmacotherapy alone, were relatively homework compliant, and improved on indices of 
anxiety and depression. This suggests that weekly sessions with the UP are tolerable in this 
population, and there is a reasonable expectation that patients will be able to engage in 
treatment-related homework assignments between sessions. However, this study also 
suggests that not all patients benefit equally from the UP. Specifically, patients higher in 
baseline emotion dysregulation and levels of neuroticism fared less well in the current trial 
than those lower on these variables. Future studies are needed to determine a) alternate 
treatment delivery options for those patients who are more severely dysregulated at baseline; 
and b) whether alternate methods to enhance emotion regulation capacity, such as 
neuromodulation, attention training, or bias modification training used prior to a course of 
treatment with the UP might enhance UP treatment outcomes in this population. Overall, 
results from this study provide a helpful first step in determining the efficacy of a 
transdiagnostic CBT approach in addressing comorbid anxiety in the context of BD.
Acknowledgments
Funding Source
This work was supported by a Postdoctoral National Research Service Award from the National Institutes of Health 
[F32 MH098490] to K. Ellard.
The authors would like to thank David Dodell-Feder, Tracie Goodness, Dianne Hezel and Kristin Szuhany for their 
assistance with independent evaluations during this study.
References
Allain N, Leven C, Falissard B, Allain JS, Batail JM, Polard E, Naudet F. Manic switches induced by 
antidepressants: an umbrella review comparing randomized controlled trials and observational 
studies. Acta Psychiatr Scand. 2016; doi: 10.1111/acps.12672
Altman EG, Hedeker D, Peterson JL, Davis JM. The Altman Self-Rating Mania Scale. Biol Psychiatry. 
1997; 42(10):948–955. DOI: 10.1016/S0006-3223(96)00548-3 [PubMed: 9359982] 
Ellard et al. Page 17
J Affect Disord. Author manuscript; available in PMC 2018 September 01.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
American Psychiatric Association. Diagnostic and statistical manual of mental disorders (DSM-5). 
American Psychiatric Pub; 2013. 
Attkisson CC, Zwick R. The Client Satisfaction Questionnaire: Psychometric properties and 
correlations with service utilization and psychotherapy outcome. Evaluation and program planning. 
1982; 5(3):233–237. [PubMed: 10259963] 
Ball JR, Mitchell PB, Corry JC, Skillecorn A, Smith M, Malhi GS. A randomized controlled trial of 
cognitive therapy for bipolar disorder: focus on long-term change. J Clin Psychiatry. 2006; 67(2):
277–286. [PubMed: 16566624] 
Bardeen JR, Fergus TA, Orcutt HK. An examination of the latent structure of the Difficulties in 
Emotion Regulation Scale. Journal of Psychopathology and Behavioral Assessment. 2012; 34(3):
382–392.
Barlow, D., Ellard, K., Fairholme, C., Farchione, T., Boisseau, C., Allen, L., Ehrenreich-May, J. 
Unified protocol for the transdiagnostic treatment of emotional disorders: Patient workbook. New 
York, NY: Oxford University Press; 2010a. 
Barlow DH, Farchione TJ, Bullis JR, Gallagher MW, Latin H, Sauer-Zavla S, Cassiello-Robbins C. 
Equivalence evaluation of the Unified Protocol for Transdiagnostic Treatment of Emotional 
Disorders compared to diagnosis-specific CBT for anxiety disorders. (Submitted). 
Barlow, DH., Farchione, TJ., Fairholme, CP., Ellard, KK., Boisseau, CL., Allen, LB., May, JTE. 
Unified protocol for transdiagnostic treatment of emotional disorders: Therapist guide. Oxford 
University Press; 2010b. 
Barlow DH, Sauer-Zavala S, Carl JR, Bullis JR, Ellard KK. The nature, diagnosis, and treatment of 
neuroticism: Back to the future. Clinical Psychological Science. 2014; 2(3):344–365.
Berg CZ, Shapiro N, Chambless DL, Ahrens AH. Are emotions frightening? II: An analogue study of 
fear of emotion, interpersonal conflict, and panic onset. Behaviour Research and Therapy. 1998; 
36(1):3–15. [PubMed: 9613013] 
Brunette MF, Noordsy DL, Xie H, Drake RE. Benzodiazepine use and abuse among patients with 
severe mental illness and co-occurring substance use disorders. Psychiatr Serv. 2003; 54(10):
1395–1401. DOI: 10.1176/appi.ps.54.10.1395 [PubMed: 14557527] 
Bruss GS, Gruenberg AM, Goldstein RD, Barber JP. Hamilton Anxiety Rating Scale Interview guide: 
joint interview and test-retest methods for interrater reliability. Psychiatry research. 1994; 53(2):
191–202. [PubMed: 7824679] 
Campbell-Sills L, Liverant GI, Brown TA. Psychometric evaluation of the behavioral inhibition/
behavioral activation scales in a large sample of outpatients with anxiety and mood disorders. 
Psychological assessment. 2004; 16(3):244. [PubMed: 15456380] 
Carver CS, White TL. Behavioral inhibition, behavioral activation, and affective responses to 
impending reward and punishment: the BIS/BAS scales. Journal of personality and social 
psychology. 1994; 67(2):319.
Chatterton ML, Stockings E, Berk M, Barendregt JJ, Carter R, Mihalopoulos C. Psychosocial therapies 
for the adjunctive treatment of bipolar disorder in adults: network meta-analysis. Br J Psychiatry. 
2017; doi: 10.1192/bjp.bp.116.195321
Costa, PT., McCrea, RR. Revised neo personality inventory (neo pi-r) and neo five-factor inventory 
(neo-ffi). Psychological Assessment Resources; 1992. 
Costa RT, Cheniaux E, Rosaes PA, Carvalho MR, Freire RC, Versiani M, Nardi AE. The effectiveness 
of cognitive behavioral group therapy in treating bipolar disorder: a randomized controlled study. 
Rev Bras Psiquiatr. 2011; 33(2):144–149. [PubMed: 21829907] 
Deckersbach T, Peters AT, Sylvia L, Urdahl A, Magalhaes PV, Otto MW, Nierenberg A. Do comorbid 
anxiety disorders moderate the effects of psychotherapy for bipolar disorder? Results from STEP-
BD. Am J Psychiatry. 2014; 171(2):178–186. DOI: 10.1176/appi.ajp.2013.13020225 [PubMed: 
24077657] 
El-Mallakh RS, Hollifield M. Comorbid anxiety in bipolar disorder alters treatment and prognosis. 
Psychiatr Q. 2008; 79(2):139–150. DOI: 10.1007/s11126-008-9071-5 [PubMed: 18491230] 
Ellard KK, Deckersbach T, Sylvia LG, Nierenberg AA, Barlow DH. Transdiagnostic treatment of 
bipolar disorder and comorbid anxiety with the unified protocol: a clinical replication series. 
Behav Modif. 2012; 36(4):482–508. DOI: 10.1177/0145445512451272 [PubMed: 22822175] 
Ellard et al. Page 18
J Affect Disord. Author manuscript; available in PMC 2018 September 01.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Ellard KK, Fairholme CP, Boisseau CL, Farchione TJ, Barlow DH. Unified protocol for the 
transdiagnostic treatment of emotional disorders: Protocol development and initial outcome data. 
Cognitive and Behavioral Practice. 2010; 17(1):88–101.
Farchione TJ, Fairholme CP, Ellard KK, Boisseau CL, Thompson-Hollands J, Carl JR, Barlow DH. 
Unified protocol for transdiagnostic treatment of emotional disorders: a randomized controlled 
trial. Behav Ther. 2012; 43(3):666–678. DOI: 10.1016/j.beth.2012.01.001 [PubMed: 22697453] 
Fava GA, Rafanelli C, Tomba E, Guidi J, Grandi S. The sequential combination of cognitive 
behavioral treatment and well-being therapy in cyclothymic disorder. Psychother Psychosom. 
2011; 80(3):136–143. DOI: 10.1159/000321575 [PubMed: 21372621] 
First, MB., Spitzer, RL., Gibbon, M., Williams, JBW. The Structured Clinical Interview for DSM-IV 
Axis I Disorders (SCID-IV), Clinician Version. Washington, D.C.: American Psychiatric 
Association; 1997. 
Fowler JC, Charak R, Elhai JD, Allen JG, Frueh BC, Oldham JM. Construct validity and factor 
structure of the difficulties in emotion regulation scale among adults with severe mental illness. 
Journal of psychiatric research. 2014; 58:175–180. [PubMed: 25171941] 
Frank E, Kupfer DJ, Thase ME, Mallinger AG, Swartz HA, Fagiolini AM, Monk T. Two-year 
outcomes for interpersonal and social rhythm therapy in individuals with bipolar I disorder. Arch 
Gen Psychiatry. 2005; 62(9):996–1004. DOI: 10.1001/archpsyc.62.9.996 [PubMed: 16143731] 
Freeman MP, Freeman SA, McElroy SL. The comorbidity of bipolar and anxiety disorders: prevalence, 
psychobiology, and treatment issues. J Affect Disord. 2002; 68(1):1–23. [PubMed: 11869778] 
Goldberg D, Fawcett J. The importance of anxiety in both major depression and bipolar disorder. 
Depress Anxiety. 2012; 29(6):471–478. DOI: 10.1002/da.21939 [PubMed: 22553107] 
Gomes BC, Abreu LN, Brietzke E, Caetano SC, Kleinman A, Nery FG, Lafer B. A randomized 
controlled trial of cognitive behavioral group therapy for bipolar disorder. Psychother Psychosom. 
2011; 80(3):144–150. DOI: 10.1159/000320738 [PubMed: 21372622] 
Gonzalez Isasi A, Echeburua E, Liminana JM, Gonzalez-Pinto A. Psychoeducation and cognitive-
behavioral therapy for patients with refractory bipolar disorder: a 5-year controlled clinical trial. 
Eur Psychiatry. 2014; 29(3):134–141. DOI: 10.1016/j.eurpsy.2012.11.002 [PubMed: 23276524] 
Gratz KL, Roemer L. Multidemensional assessment of emotion regulation and dysregulation: 
Development, factor structure, and initial validation of the difficulties in emotion regulation scale. 
Journal of Psychopathology and Behavioral Assessment. 2004; 26:41–45.
Gruber J, Harvey AG, Gross JJ. When trying is not enough: emotion regulation and the effort-success 
gap in bipolar disorder. Emotion. 2012; 12(5):997–1003. DOI: 10.1037/a0026822 [PubMed: 
22251049] 
Hamilton MAX. The assessment of anxiety states by rating. British journal of medical psychology. 
1959; 32(1):50–55. [PubMed: 13638508] 
Hamilton M. A rating scale for depression. J Neurol Neurosurg Psychiatry. 1960; 23:56–62. [PubMed: 
14399272] 
Heissler J, Kanske P, Schonfelder S, Wessa M. Inefficiency of emotion regulation as vulnerability 
marker for bipolar disorder: evidence from healthy individuals with hypomanic personality. J 
Affect Disord. 2014; 152–154:83–90. DOI: 10.1016/j.jad.2013.05.001
Hoertnagl CM, Muehlbacher M, Biedermann F, Yalcin N, Baumgartner S, Schwitzer G, Hofer A. 
Facial emotion recognition and its relationship to subjective and functional outcomes in remitted 
patients with bipolar I disorder. Bipolar Disord. 2011; 13(5–6):537–544. DOI: 10.1111/j.
1399-5618.2011.00947.x [PubMed: 22017222] 
Ives-Deliperi VL, Howells F, Stein DJ, Meintjes EM, Horn N. The effects of mindfulness-based 
cognitive therapy in patients with bipolar disorder: a controlled functional MRI investigation. J 
Affect Disord. 2013; 150(3):1152–1157. DOI: 10.1016/j.jad.2013.05.074 [PubMed: 23790741] 
Jones SH, Smith G, Mulligan LD, Lobban F, Law H, Dunn G, Morrison AP. Recovery-focused 
cognitive-behavioural therapy for recent-onset bipolar disorder: randomised controlled pilot trial. 
Br J Psychiatry. 2015; 206(1):58–66. DOI: 10.1192/bjp.bp.113.141259 [PubMed: 25213157] 
Kanske P, Heissler J, Schonfelder S, Forneck J, Wessa M. Neural correlates of emotional distractibility 
in bipolar disorder patients, unaffected relatives, and individuals with hypomanic personality. Am J 
Ellard et al. Page 19
J Affect Disord. Author manuscript; available in PMC 2018 September 01.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Psychiatry. 2013; 170(12):1487–1496. DOI: 10.1176/appi.ajp.2013.12081044 [PubMed: 
23982186] 
Kessler RC, Akiskal HS, Ames M, Birnbaum H, Greenberg P, Hirschfeld RM, Wang PS. Prevalence 
and effects of mood disorders on work performance in a nationally representative sample of U.S. 
workers. Am J Psychiatry. 2006; 163(9):1561–1568. DOI: 10.1176/ajp.2006.163.9.1561 [PubMed: 
16946181] 
Kessler RC, Berglund P, Demler O, Jin R, Merikangas KR, Walters EE. Lifetime prevalence and age-
of-onset distributions of DSM-IV disorders in the National Comorbidity Survey Replication. Arch 
Gen Psychiatry. 2005; 62(6):593–602. DOI: 10.1001/archpsyc.62.6.593 [PubMed: 15939837] 
Lam DH, Watkins ER, Hayward P, Bright J, Wright K, Kerr N, Sham P. A randomized controlled study 
of cognitive therapy for relapse prevention for bipolar affective disorder: outcome of the first year. 
Arch Gen Psychiatry. 2003; 60(2):145–152. [PubMed: 12578431] 
Larsen DL, Attkisson CC, Hargreaves WA, Nguyen TD. Assessment of client/patient satisfaction: 
development of a general scale. Eval Program Plann. 1979; 2(3):197–207. [PubMed: 10245370] 
Lee DJ, Witte TK, Bardeen JR, Davis MT, Weathers FW. A factor analytic evaluation of the difficulties 
in emotion regulation scale. Journal of clinical psychology. 2016; 72(9):933–946. [PubMed: 
27018649] 
Lee JH, Dunner DL. The effect of anxiety disorder comorbidity on treatment resistant bipolar 
disorders. Depress Anxiety. 2008; 25(2):91–97. DOI: 10.1002/da.20279 [PubMed: 17311265] 
Leon AC, Solomon DA, Mueller TI, Endicott J, Posternak M, Judd LL, Keller MB. A brief assessment 
of psychosocial functioning of subjects with bipolar I disorder: the LIFE-RIFT. The Journal of 
nervous and mental disease. 2000; 188(12):805–812. [PubMed: 11191580] 
Leon AC, Solomon DA, Mueller TI, Turvey CL, Endicott J, Keller MB. The Range of Impaired 
Functioning Tool (LIFE-RIFT): a brief measure of functional impairment. Psychol Med. 1999; 
29(4):869–878. [PubMed: 10473314] 
Merikangas KR, Akiskal HS, Angst J, Greenberg PE, Hirschfeld RM, Petukhova M, Kessler RC. 
Lifetime and 12-month prevalence of bipolar spectrum disorder in the National Comorbidity 
Survey replication. Arch Gen Psychiatry. 2007; 64(5):543–552. DOI: 10.1001/archpsyc.64.5.543 
[PubMed: 17485606] 
Merikangas KR, Jin R, He JP, Kessler RC, Lee S, Sampson NA, Zarkov Z. Prevalence and correlates 
of bipolar spectrum disorder in the world mental health survey initiative. Arch Gen Psychiatry. 
2011; 68(3):241–251. DOI: 10.1001/archgenpsychiatry.2011.12 [PubMed: 21383262] 
Meyer TD, Hautzinger M. Cognitive behaviour therapy and supportive therapy for bipolar disorders: 
relapse rates for treatment period and 2-year follow-up. Psychol Med. 2012; 42(7):1429–1439. 
DOI: 10.1017/S0033291711002522 [PubMed: 22099722] 
Miklowitz DJ, Otto MW, Frank E, Reilly-Harrington NA, Wisniewski SR, Kogan JN, Sachs GS. 
Psychosocial treatments for bipolar depression: a 1-year randomized trial from the Systematic 
Treatment Enhancement Program. Arch Gen Psychiatry. 2007; 64(4):419–426. DOI: 10.1001/
archpsyc.64.4.419 [PubMed: 17404119] 
Mueser KT, Rosenberg SD, Xie H, Jankowski MK, Bolton EE, Lu W, Wolfe R. A randomized 
controlled trial of cognitive-behavioral treatment for posttraumatic stress disorder in severe mental 
illness. Journal of consulting and clinical psychology. 2008; 76(2):259. [PubMed: 18377122] 
Muhtadie L, Johnson SL, Carver CS, Gotlib IH, Ketter TA. A profile approach to impulsivity in 
bipolar disorder: the key role of strong emotions. Acta Psychiatr Scand. 2014; 129(2):100–108. 
DOI: 10.1111/acps.12136 [PubMed: 23600731] 
Nolen-Hoeksema S, Morrow J. A prospective study of depression and posttraumatic stress symptoms 
after a natural disaster: the 1989 Loma Prieta Earthquake. J Pers Soc Psychol. 1991; 61(1):115–
121. [PubMed: 1890582] 
Otto MW, Simon NM, Wisniewski SR, Miklowitz DJ, Kogan JN, Reilly-Harrington NA, Investigators 
S-B. Prospective 12-month course of bipolar disorder in out-patients with and without comorbid 
anxiety disorders. Br J Psychiatry. 2006; 189:20–25. DOI: 10.1192/bjp.bp.104.007773 [PubMed: 
16816301] 
Pacchiarotti I, Bond DJ, Baldessarini RJ, Nolen WA, Grunze H, Licht RW, Vieta E. The International 
Society for Bipolar Disorders (ISBD) task force report on antidepressant use in bipolar disorders. 
Ellard et al. Page 20
J Affect Disord. Author manuscript; available in PMC 2018 September 01.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Am J Psychiatry. 2013; 170(11):1249–1262. DOI: 10.1176/appi.ajp.2013.13020185 [PubMed: 
24030475] 
Parikh SV, Zaretsky A, Beaulieu S, Yatham LN, Young LT, Patelis-Siotis I, Streiner DL. A randomized 
controlled trial of psychoeducation or cognitive-behavioral therapy in bipolar disorder: a Canadian 
Network for Mood and Anxiety treatments (CANMAT) study [CME]. J Clin Psychiatry. 2012; 
73(6):803–810. DOI: 10.4088/JCP.11m07343 [PubMed: 22795205] 
Perich T, Manicavasagar V, Mitchell PB, Ball JR, Hadzi-Pavlovic D. A randomized controlled trial of 
mindfulness-based cognitive therapy for bipolar disorder. Acta Psychiatr Scand. 2013; 127(5):
333–343. DOI: 10.1111/acps.12033 [PubMed: 23216045] 
Peterson RA, Heilbronner RL. The anxiety sensitivity index:: Construct validity and factor analytic 
structure. Journal of Anxiety Disorders. 1987; 1(2):117–121.
Phillips ML, Vieta E. Identifying functional neuroimaging biomarkers of bipolar disorder: toward 
DSM-V. Schizophr Bull. 2007; 33(4):893–904. DOI: 10.1093/schbul/sbm060 [PubMed: 
17562698] 
Post RM, Altshuler LL, Leverich GS, Frye MA, Nolen WA, Kupka RW, Mintz J. Mood switch in 
bipolar depression: comparison of adjunctive venlafaxine, bupropion and sertraline. Br J 
Psychiatry. 2006; 189:124–131. DOI: 10.1192/bjp.bp.105.013045 [PubMed: 16880481] 
Primakoff L, Epstein N, Covi L. Homework compliance: An uncontrolled variable in cognitive therapy 
outcome research. Behavior Therapy. 1986; 17:433–446.
Provencher MD, Hawke LD, Thienot E. Psychotherapies for comorbid anxiety in bipolar spectrum 
disorders. J Affect Disord. 2011; 133(3):371–380. DOI: 10.1016/j.jad.2010.10.040 [PubMed: 
21093062] 
Reilly-Harrington NA, Deckersbach T, Knauz R, Wu Y, Tran T, Eidelman P, Nierenberg AA. Cognitive 
behavioral therapy for rapid-cycling bipolar disorder: a pilot study. J Psychiatr Pract. 2007; 13(5):
291–297. DOI: 10.1097/01.pra.0000290667.02484.3d [PubMed: 17890977] 
Reiss S, Peterson RA, Gursky DM, McNally RJ. Anxiety sensitivity, anxiety frequency and the 
prediction of fearfulness. Behav Res Ther. 1986; 24(1):1–8. [PubMed: 3947307] 
Robins RW, Fraley RC, Roberts BW, Trzesniewski KH. A longitudinal study of personality change in 
young adulthood. Journal of personality. 2001; 69(4):617–640. [PubMed: 11497032] 
Rosenberg SD, Mueser KT, Jankowski MK, Salyers MP, Acker K. Cognitive-Behavioral Treatmenzt of 
PTSD in Severe Mental Illness: Results of a Pilot Study. American Journal of Psychiatric 
Rehabilitation. 2004; 7(2):171–186.
Rush AJ, Trivedi MH, Ibrahim HM, Carmody TJ, Arnow B, Klein DN, Keller MB. The 16-Item Quick 
Inventory of Depressive Symptomatology (QIDS), clinician rating (QIDS-C), and self-report 
(QIDS-SR): a psychometric evaluation in patients with chronic major depression. Biol Psychiatry. 
2003; 54(5):573–583. [PubMed: 12946886] 
Salcedo S, Gold AK, Sheikh S, Marcus PH, Nierenberg AA, Deckersbach T, Sylvia LG. Empirically 
supported psychosocial interventions for bipolar disorder: Current state of the research. J Affect 
Disord. 2016; 201:203–214. DOI: 10.1016/j.jad.2016.05.018 [PubMed: 27243619] 
Samalin L, de Chazeron I, Vieta E, Bellivier F, Llorca PM. Residual symptoms and specific functional 
impairments in euthymic patients with bipolar disorder. Bipolar Disord. 2016; 18(2):164–173. 
DOI: 10.1111/bdi.12376 [PubMed: 26946486] 
Sasson Y, Chopra M, Harrari E, Amitai K, Zohar J. Bipolar comorbidity: from diagnostic dilemmas to 
therapeutic challenge. Int J Neuropsychopharmacol. 2003; 6(2):139–144. DOI: 10.1017/
S1461145703003432 [PubMed: 12890307] 
Scott J, Paykel E, Morriss R, Bentall R, Kinderman P, Johnson T, Hayhurst H. Cognitive-behavioural 
therapy for severe and recurrent bipolar disorders: randomised controlled trial. Br J Psychiatry. 
2006; 188:313–320. DOI: 10.1192/bjp.188.4.313 [PubMed: 16582056] 
Shear MK, Vander Bilt J, Rucci P, Endicott J, Lydiard B, Otto MW, Ali A. Reliability and validity of a 
structured interview guide for the Hamilton Anxiety Rating Scale (SIGH-A). Depression and 
anxiety. 2001; 13(4):166–178. [PubMed: 11413563] 
Simon NM, Otto MW, Wisniewski SR, Fossey M, Sagduyu K, Frank E, Pollack MH. Anxiety disorder 
comorbidity in bipolar disorder patients: data from the first 500 participants in the Systematic 
Ellard et al. Page 21
J Affect Disord. Author manuscript; available in PMC 2018 September 01.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Treatment Enhancement Program for Bipolar Disorder (STEP-BD). Am J Psychiatry. 2004; 
161(12):2222–2229. DOI: 10.1176/appi.ajp.161.12.2222 [PubMed: 15569893] 
Snow NL, Ward RM, Becker SP, Raval VV. Measurement invariance of the difficulties in emotion 
regulation scale in India and the United States. Journal of Educational and Developmental 
Psychology. 2013; 3(1):147.
Solomon DA, Leon AC, Coryell WH, Endicott J, Li C, Fiedorowicz JG, Keller MB. Longitudinal 
course of bipolar I disorder: duration of mood episodes. Archives of general psychiatry. 2010; 
67(4):339–347. [PubMed: 20368510] 
Stratford HJ, Cooper MJ, Di Simplicio M, Blackwell SE, Holmes EA. Psychological therapy for 
anxiety in bipolar spectrum disorders: a systematic review. Clin Psychol Rev. 2015; 35:19–34. 
DOI: 10.1016/j.cpr.2014.11.002 [PubMed: 25462111] 
Suppes T, Dennehy EB, Hirschfeld RM, Altshuler LL, Bowden CL, Calabrese JR. Texas Consensus 
Conference Panel on Medication Treatment of Bipolar, D. The Texas implementation of 
medication algorithms: update to the algorithms for treatment of bipolar I disorder. J Clin 
Psychiatry. 2005; 66(7):870–886. [PubMed: 16013903] 
Swann AC, Lijffijt M, Lane SD, Steinberg JL, Moeller FG. Increased trait-like impulsivity and course 
of illness in bipolar disorder. Bipolar Disord. 2009; 11(3):280–288. DOI: 10.1111/j.
1399-5618.2009.00678.x [PubMed: 19419385] 
Swartz HA, Frank E, Cheng Y. A randomized pilot study of psychotherapy and quetiapine for the acute 
treatment of bipolar II depression. Bipolar Disord. 2012; 14(2):211–216. DOI: 10.1111/j.
1399-5618.2012.00988.x [PubMed: 22420597] 
Swartz HA, Swanson J. Psychotherapy for Bipolar Disorder in Adults: A Review of the Evidence. 
Focus (Am Psychiatr Publ). 2014; 12(3):251–266. DOI: 10.1176/appi.focus.12.3.251 [PubMed: 
26279641] 
Thomas J, Knowles R, Tai S, Bentall RP. Response styles to depressed mood in bipolar affective 
disorder. J Affect Disord. 2007; 100(1–3):249–252. DOI: 10.1016/j.jad.2006.10.017 [PubMed: 
17134763] 
Tondo L, Vazquez G, Baldessarini RJ. Mania associated with antidepressant treatment: comprehensive 
meta-analytic review. Acta Psychiatr Scand. 2010; 121(6):404–414. DOI: 10.1111/j.
1600-0447.2009.01514.x [PubMed: 19958306] 
Trajković G, Starčević V, Latas M, Leštarević M, Ille T, Bukumirić Z, Marinković J. Reliability of the 
Hamilton Rating Scale for Depression: A meta-analysis over a period of 49years. Psychiatry 
research. 2011; 189(1):1–9. [PubMed: 21276619] 
Trapnell PD, Campbell JD. Private self-consciousness and the five-factor model of personality: 
distinguishing rumination from reflection. J Pers Soc Psychol. 1999; 76(2):284–304. [PubMed: 
10074710] 
Trivedi MH, Rush A, Ibrahim H, Carmody T, Biggs M, Suppes T, Dennehy E. The Inventory of 
Depressive Symptomatology, Clinician Rating (IDS-C) and Self-Report (IDS-SR), and the Quick 
Inventory of Depressive Symptomatology, Clinician Rating (QIDS-C) and Self-Report (QIDS-SR) 
in public sector patients with mood disorders: a psychometric evaluation. Psychological medicine. 
2004; 34(01):73–82. [PubMed: 14971628] 
Van der Gucht E, Morriss R, Lancaster G, Kinderman P, Bentall RP. Psychological processes in bipolar 
affective disorder: negative cognitive style and reward processing. Br J Psychiatry. 2009; 194(2):
146–151. DOI: 10.1192/bjp.bp.107.047894 [PubMed: 19182176] 
Van Dijk S, Jeffrey J, Katz MR. A randomized, controlled, pilot study of dialectical behavior therapy 
skills in a psychoeducational group for individuals with bipolar disorder. J Affect Disord. 2013; 
145(3):386–393. DOI: 10.1016/j.jad.2012.05.054 [PubMed: 22858264] 
Van Rheenen TE, Murray G, Rossell SL. Emotion regulation in bipolar disorder: profile and utility in 
predicting trait mania and depression propensity. Psychiatry Res. 2015; 225(3):425–432. DOI: 
10.1016/j.psychres.2014.12.001 [PubMed: 25537486] 
Vazquez GH, Baldessarini RJ, Tondo L. Co-occurrence of anxiety and bipolar disorders: clinical and 
therapeutic overview. Depress Anxiety. 2014; 31(3):196–206. DOI: 10.1002/da.22248 [PubMed: 
24610817] 
Ellard et al. Page 22
J Affect Disord. Author manuscript; available in PMC 2018 September 01.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Williams JM, Alatiq Y, Crane C, Barnhofer T, Fennell MJ, Duggan DS, Goodwin GM. Mindfulness-
based Cognitive Therapy (MBCT) in bipolar disorder: preliminary evaluation of immediate effects 
on between-episode functioning. J Affect Disord. 2008; 107(1–3):275–279. DOI: 10.1016/j.jad.
2007.08.022 [PubMed: 17884176] 
Williams KE, Chambless DL, Aherns A. Are emotions frightening? An extension of the fear of fear 
construct. Behavior Research and Therapy. 1997; 33:579–583.
Wolkenstein L, Zwick JC, Hautzinger M, Joormann J. Cognitive emotion regulation in euthymic 
bipolar disorder. J Affect Disord. 2014; 160:92–97. DOI: 10.1016/j.jad.2013.12.022 [PubMed: 
24445131] 
Young R, Biggs J, Ziegler V, Meyer D. A rating scale for mania: reliability, validity and sensitivity. 
The British Journal of Psychiatry. 1978; 133(5):429–435. [PubMed: 728692] 
Zaretsky A, Lancee W, Miller C, Harris A, Parikh SV. Is cognitive-behavioural therapy more effective 
than psychoeducation in bipolar disorder? Can J Psychiatry. 2008; 53(7):441–448. DOI: 
10.1177/070674370805300709 [PubMed: 18674402] 
Ellard et al. Page 23
J Affect Disord. Author manuscript; available in PMC 2018 September 01.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Highlights
• Examines a transdiagnostic CBT approach to treating anxiety in bipolar 
disorder (UP).
• Treatment with the UP demonstrated feasibility and acceptability.
• The UP adjunctive to medication TAU resulted in greater reductions in 
anxiety.
• The UP adjunctive to TAU also resulted in greater reductions in depression.
• UP adjunctive to TAU was a viable approach to treating anxiety in bipolar 
disorder.
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Fig 1. 
CONSORT diagram
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